TSTickerStarGet alerts

bioAffinity Technologies prices approximately $4 million registered direct offering of common stock and concurrent private placement of warrants

On October 8, 2026, bioAffinity Technologies entered into a securities purchase agreement with an institutional investor for a registered direct offering of 116,545 shares of common stock at $6.122 per share and pre-funded warrants for 536,836 shares at $6.115 per pre-funded warrant, together with a concurrent private placement of unregistered warrants for an aggregate 980,072 shares at an exercise price of $6.122 per share. Gross proceeds are expected to be approximately $4 million before placement agent fees a...

Share this story

Key takeaways

  • Offering size: The combined registered direct offering and concurrent private placement is expected to produce approximately $4 million in gross proceeds.

  • Securities issued: 116,545 shares of common stock at $6.122 per share, pre-funded warrants for 536,836 shares at $6.115 per pre-funded warrant, and unregistered warrants for 980,072 shares with a $6.122 exercise price, five-year term, and exercisability conditioned on stockholder approval.

  • Placement agent compensation: WallachBeth Capital, LLC acted as sole placement agent, receiving a 7.5% cash fee, a $70,000 expense reimbursement, and placement agent warrants for 3% of the aggregate shares and pre-funded warrants sold (19,602 shares) at $6.122.

  • Closing: The offering closed on October 9, 2026, the day after the pricing announcement; press releases for both pricing (Ex-99.1, Oct 8) and closing (Ex-99.2, Oct 9) were furnished as exhibits.

  • ATM suspension: The Company suspended its prospectus supplement and related prospectus filed May 27, 2025, for the At the Market Issuance Sales Agreement with WallachBeth dated May 22, 2025, and will not make further sales under that sales agreement until a new prospectus supplement is filed.

  • Use of proceeds: Net proceeds are intended for working capital, to support expected growing sales of CyPath Lung, and for general corporate purposes.

  • Registration rights and covenants: The Company entered into a registration rights agreement requiring filing of a resale registration statement within 45 days and effectiveness within 90 days (or 120 days under full SEC review); the agreement also includes a six-month placement agent right of first refusal and 12-month tail.

Key metrics

Common stock issued in registered directOctober 8-9, 2026
116,545 shares
Pre-funded warrants issued (underlying shares)October 8-9, 2026
536,836 shares
Unregistered warrants issued (underlying shares)October 8-9, 2026
980,072 shares
Common stock priceOctober 8, 2026
$6.122
Pre-funded warrant priceOctober 8, 2026
$6.115
Warrant exercise priceOctober 8, 2026
$6.122
Gross proceedsOctober 8-9, 2026
approximately $4 million

Disclosure changes

  • ATM prospectus supplement suspension

    On October 8, 2026, the Company suspended the prospectus supplement and related prospectus filed May 27, 2025, relating to the At the Market Issuance Sales Agreement dated May 22, 2025 with WallachBeth Capital, and will not make further sales under that sales agreement until a new prospectus supplement is filed; the underlying sales agreement otherwise remains in full force and effect.

    Discontinues use of the prior ATM facility, which had been a potential source of equity issuance; any resumption would require a new prospectus supplement.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow BIAF in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert